Artificial Intelligence in Indonesian Healthcare

By Sumona Bose

February 14, 2024

AI’s Rising Influence in Global Healthcare

Artificial intelligence (AI) is making waves in the healthcare industry worldwide. OpenAI’s ChatGPT, an AI language model, astounded the medical community by acing the United States Medical Licensing Exam without specialised training. Google’s Med-PaLM 2 mirrored this success, demonstrating AI’s potential to absorb and apply vast medical knowledge. AI’s  power also extends to research, with McMaster University and MIT using it to discover new antibacterial molecules, marking a significant step in the fight against antimicrobial resistance. The East Asian and Pacific region has also seen greater increase in AI employability in healthcare market.

Asia Pacific Healthcare AI Market Growth Outlook 2021-2027
Figure 1: Asia Pacific’s AI Market Report.

AI and Healthcare in Indonesia: Opportunities and Challenges

Indonesia, with its low physician-to-population ratio, stands to benefit immensely from AI’s potential. AI-powered chatbots, integrated with data from various sources, could enhance healthcare accessibility across the archipelago. The integration of AI with digital health platforms like Halodoc could potentially improve the quality of healthcare services in Indonesia. However, the journey towards AI integration is not without challenges. Bias in AI models, primarily trained on medical literature from high-income countries, is a significant concern. Indonesia must consider this bias when integrating AI with existing digital healthcare services. The use of local data, such as from Halodoc, is crucial for effective AI deployment in Indonesian healthcare.

Addressing Privacy Concerns and the Need for Regulation

Data acquisition for AI model training also raises serious privacy concerns. Despite the enactment of the Personal Data Protection Law in 2022, public unease over sensitive data leaks remains high in Indonesia. The country can learn from South Korea’s model of a centralised, secure, and ethical data-sharing system to build its national AI-based healthcare data ecosystem. The future of AI-enhanced healthcare necessitates a reimagining of healthcare education. Future professionals must be prepared to synergise with AI, requiring the development of AI-focused modules in medical and health curricula. By promoting stringent regulations, prioritising data privacy, and reimagining healthcare education, Indonesia can pave the way for a future where AI and human expertise harmoniously work together.

In conclusion, the integration of AI in healthcare presents a promising future for Indonesia. With careful consideration of potential challenges and the implementation of robust regulations, the country can leverage AI’s potential to improve healthcare accessibility and quality across the archipelago.

Reference url

Recent Posts

Advancing B7-H3 Targeted Therapy for Relapsed Extensive-Stage Small Cell Lung Cancer

By HEOR Staff Writer

April 15, 2026

The FDA’s Priority Review of ifinatamab deruxtecan was recently announced, a potential first-in-class B7-H3 targeted therapy. The Biologics License Application for ifinatamab deruxtecan (I-DXd), a B7-H3 directed DXd antibody drug conjugate (ADC), has been accepted with a Prescription Drug User Fe...
Advancing Inclusive Healthcare Strategies Through Social Impact and Sustainability
In this update we examine how Novartis is embedding inclusive healthcare strategies into its core business by launching ambitious long-term Social Impact and Sustainability (SI&S) targets that reach to 2040. These targets integrate innovation, access to medicines, global health, environmental...
Advancing Access: Generic Dapagliflozin Approval Enhanced for Type 2 Diabetes Treatment

By João L. Carapinha

April 14, 2026

The U.S. Food and Drug Administration has issued the generic dapagliflozin approval, clearing the first generic versions of FARXIGA (dapagliflozin) tablets. This decision significantly improves affordability and access to an important SGLT2 inhibitor for adults with type 2 diabetes. ...